BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

Tricuspid valve repair with the experimental Pascal device sustained significant early reductions in tricuspid regurgitation and improved quality of life, 1-year results from the CLASP-TR study show. ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

Hausleiter J. First commercial multicenter experience with the PASCAL transcatheter valve repair system for tricuspid regurgitation. Presented at: TVT 2021. July 21. 2021. Miami, FL. MIAMI, FL—The ...

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...

Transcatheter tricuspid valve repair with the PASCAL system appeared safe, with preliminary promise in reducing regurgitation and symptoms, the early feasibility CLASP TR trial showed. Major adverse ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...

SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...